Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

Richard Tsien, PhD, director of the Neuroscience Institute at NYU Langone Medical Center, will deliver the next web-based Discovery Lecture.

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.